Biosimilars present a new treatment option for patients with inflammatory bowel disease (IBD), but both clinicians and patients aren’t sure about their efficacy and safety. Confusing terminology and contradictory information, particularly limited knowledge of what it means for a drug to be interchangeable according to the FDA, have caused the U.S. to lag behind Europe in the utilization of these drugs. However, biosimilars are highly similar to approved biologic agents, and are comprehensively developed and tested.
Learn about biosimilars with a new on-demand offering to increase your confidence and assist with dispelling patient uncertainty.
In this on-demand virtual symposium from the 2022 Crohn’s & Colitis Congress®, Making the Switch from Biologics to Biosimilars in IBD: Knowledge Over Skepticism, Edward Loftus, MD, AGAF, Shubha Bhat, PharmD, MS, and Christina Ha, MD, AGAF, will provide you with the latest information on making the switch from using biologics to biosimilars. Learn about:
- The details and terminology surrounding interchangeability and substitution.
- The NOR-SWITCH clinical trial data, Cleveland Clinic’s study on biosimilars and real-world evidence to assess whether biosimilars can assist in your practice.
- Guidance on how to implement team-based strategies to enhance shared decision-making as well, so you can inform your patients of their options and reach optimal outcomes.
This activity offers CME/CE credit for gastroenterologists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists, and is supported by educational funding provided by Amgen.
